当前位置: X-MOL 学术Lipids Health Dis. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study
Lipids in Health and Disease ( IF 3.9 ) Pub Date : 2021-08-21 , DOI: 10.1186/s12944-021-01514-9
Nariman Moradi 1 , Fatima Zahraa Fouani 2 , Akram Vatannejad 3 , Abbas Bakhti Arani 4 , Soraya Shahrzad 4 , Reza Fadaei 5
Affiliation  

Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD. In this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits. Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p < 0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p < 0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI). The present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.

中文翻译:

确诊为冠状动脉疾病 (CAD) 患者的血清 Asprosin 水平:一项病例对照研究

冠状动脉疾病 (CAD) 被认为是一种多方面的慢性炎症性疾病,由于心房壁中脂质的积累,导致心肌供血减少。内脏性肥胖与脂肪因子释放中断在其发病机制中起关键作用。Asprosin 是一种新发现的空腹诱导的糖原性脂肪因子,与代谢紊乱有关,如 II 型糖尿病和多囊卵巢综合征。预设研究旨在评估 CAD 情况下的循环白脂素。在这项研究中,测定了 88 名 CAD 患者和 88 名非 CAD 健康对照者的血清白脂素水平。使用ELISA试剂盒评估血清IL-6、TNF-α、白脂素和脂联素。结果:与非 CAD 受试者相比,CAD 患者的血清 asprosin 更高(7.84 ± 2.08 对 5.02 ± 1. 29 μg/mL,p < 0.001)。同样,CAD 组的血清 TNF-α 和 IL-6 显着升高(p < 0.001)。然而,与非 CAD 受试者相比,CAD 组的循环脂联素减少 (p < 0.001)。此外,血清白脂素水平与 BMI、FBG、HOMA-IR、TG 和 TC 直接相关。逻辑回归分析表明,在调整潜在混杂因素(年龄、性别和 BMI)后,白脂素水平与发生 CAD 的风险增加相关(优势比:3.01, 95% CI:2.16, 4.20 和 p < 0.001)。本研究结果表明血清白脂素可能与 CAD 的发病机制有关,特别是通过胰岛素抵抗和血脂异常。与非 CAD 受试者相比,CAD 组的循环脂联素减少 (p < 0.001)。此外,血清白脂素水平与 BMI、FBG、HOMA-IR、TG 和 TC 直接相关。逻辑回归分析表明,在调整潜在混杂因素(年龄、性别和 BMI)后,白脂素水平与发生 CAD 的风险增加相关(优势比:3.01, 95% CI:2.16, 4.20 和 p < 0.001)。本研究结果表明血清白脂素可能与 CAD 的发病机制有关,特别是通过胰岛素抵抗和血脂异常。与非 CAD 受试者相比,CAD 组的循环脂联素减少 (p < 0.001)。此外,血清白脂素水平与 BMI、FBG、HOMA-IR、TG 和 TC 直接相关。逻辑回归分析表明,在调整潜在混杂因素(年龄、性别和 BMI)后,白脂素水平与发生 CAD 的风险增加相关(优势比:3.01, 95% CI:2.16, 4.20 和 p < 0.001)。本研究结果表明血清白脂素可能与 CAD 的发病机制有关,特别是通过胰岛素抵抗和血脂异常。16, 4.20 和 p < 0.001),在调整了潜在的混杂因素(年龄、性别和 BMI)后。本研究结果表明血清白脂素可能与 CAD 的发病机制有关,特别是通过胰岛素抵抗和血脂异常。16, 4.20 和 p < 0.001),在调整了潜在的混杂因素(年龄、性别和 BMI)后。本研究结果表明血清白脂素可能与 CAD 的发病机制有关,特别是通过胰岛素抵抗和血脂异常。
更新日期:2021-08-21
down
wechat
bug